Multiple Myeloma is a neoplastic disorder of plasma cells and primarily involves the
|
|
- Clinton Foster
- 8 years ago
- Views:
Transcription
1 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, Original Article Tc 99m Sestamibi Scanning in Multiple Myeloma a New look with SPECT-CT Karuna Luthra 1, Abhay Bhave 2, RD Lele 3 Abstract A variety of diagnostic tools including biochemistry, radiological imaging bone marrow studies and recently metabolic imaging with FDG PET are used for assessment of disease extent in myeloma. Aim : To evaluate the role of metabolic imaging with Tc 99m Sestamibi (Mibi) SPECT-CT in Multiple myeloma. Materials and Methods: Patients in various stages of Myeloma were scanned after 20mCi Tc99mSestamibi was injected i/v. Whole body planar scans were obtained with a dual head gamma camera and SPECT-CT imaging was done. Images were analyzed for degree and extent of abnormal Mibi uptake, extent of lesions seen on low-dose CT and fusion of these images. Results : 112 Whole body Sestamibi Scans were performed in 84 patients (46 Males; 38 Females). Out of these 24 (28.5%) were recently diagnosed cases (Pre-therapy); 35 (41.7 %) were follow-up cases who had received Chemotherapy in the past (Post-therapy), there were 2 cases (2.3%) of Smouldering Myeloma, 4 cases (4.7 %) of Plasmacytoma, 13 cases (15.5 %) of MGUS (Monoclonal gammopathy of Unknown Significance) and 3 cases (3.6%) of suspected Myeloma (not biopsy confirmed). Myeloma lesions showed good concentration of Mibi. Additionally, the CT scan component of SPECT-CT allowed visualization of osteolytic lesions of myeloma. Mibi uptake becomes positive on scan earlier than radiological changes and in follow-up cases, the presence or absence of Mibi uptake could differentiate active from old burnt-out lesions. Whole body scan could detect additional lesions in Plasmacytoma patients. Patients of MGUS showed poor concentration of Sestamibi. Conclusion : Whole body Sestamibi Imaging (WBSI) is very useful for evaluating the extent of disease in multiple myeloma. Being a metabolic imaging modality it is superior to radiological (X-ray or CT) assessment alone, and where FDG PET scan is not available, it is a valuable tool for myeloma assessment at a much lower cost. 1 Consultant, Dept. of Nuclear Medicine, 2 Consultant, Dept of Haematology, 3 Director, Deptt of Nuclear Medicine, Lilavati Hospital and Research Centre, Mumbai Received: ; Revised: ; Accepted: Introduction Multiple Myeloma is a neoplastic disorder of plasma cells and primarily involves the bone marrow. 1 It is an incurable, relapsing disease and needs constant monitoring. It accounts for approximately 1% of all malignant diseases and represents about 10% of hematologic malignancies. The median age at diagnosis is 65 years, and about 3% of patients are younger than 40 years. 2 Haematological parameters like serum globulin level, serum protein electrophoresis, Free light chains with ratio, Beta 2 Microglobin level; Urine for Bence Jones protein and Bone marrow aspiration and biopsy with cytogenetics and FISH (Fluorescent In Situ Hybridisation) for chromosomal defects are routinely used for diagnosis and follow-up of patients. 3 Osteolytic bone lesions are seen in up to 90% of patients 4 which can be detected on plain X-rays and Whole body skeletograms 5 and have been conventionally used for assessing the extent of bone lesions, but unfortunately these have limited sensitivity. 6 CT scans have better sensitivity for detection of lytic lesions 7 than plain X-rays. MRI is very useful for detection of marrow disease and assess sites for biopsy for a better diagnosis, but does have some inherent limitations in follow-up evaluations. 8 Nuclear Bone scanning with bone agents (Tc99m- JAPI september 2014 VOL
2 30 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, 2014 of Parathyroid adenomas and tumors in Brain and Breast (Scintimammography) in all Nuclear Medicine departments. It was first used for Myeloma imaging in There have been few reports of its use in imaging multiple myeloma, but it never became popular in clinical practice. All previous reports have discussed planar imaging with Tc Sestamibi (Mibi) and few used SPECT or SPECT-CT. Apart from detection of active disease, uptake patterns of Mibi in myeloma are known to have significant prognostic value. 20,21 Sestamibi, being a substrate for p-glycoprotein in cells, is a unique tracer which can help predict resistence of tumor cells to chemotherapy. With all these aspects in mind we decided to study a series of patients with multiple myeloma with Tc99m- Sestamibi with planar and SPECT-CT scanning. Fig. 1 : Upper left low dose CT image, Upper right SPECT transaxial slice which shows the uptake of radiotracer, Bottom left Fused image where the SPECT image is superimposed on the CT image, Bottom right MIP (projection) image. In the example above - the area of uptake marked by the red icon is localized to an enlarged right sided submandibular lymph node Diphosphonate Bone Scans) have poor sensitivity for detection of osteolytic myeloma bone disease 9 since these lesions do not produce a significant concomitant osteoblastic reaction and may not concentrate the bone tracer. Hence this modality in not recommended in myeloma assessment. 10 PET-CT scanning with FDG (Fluoro-deoxy glucose) has emerged as an excellent technique for imaging myeloma lesions, 11 but still has limited availability in our country and is expensive. We explored the use of another tracer Tc 99m Sestamibi for imaging myeloma. This tracer is easily available in all Nuclear-medicine departments, is cheaper than F18-FDG and can be used without any additional cost of equipment or personnel. Tc 99m Sestamibi Tc-Sestamibi (Methoxyisobutyl Isonitrile) is a radiotracer which concentrates in mitochondria of cells. 12 Tracer uptake in cells is linked to the mitochondrial transmembrane electric potentials which is a function of the metabolic activity of cells. It is routinely used for Myocardial Perfusion Imaging (earlier called Stress Thallium ). Physiological uptake of Sestamibi is seen in salivary glands, thyroid, myocardium, liver, spleen, gall bladder and intestines (through gall bladder excretion), kidneys and urinary tract (through urinary excretion). This tracer is also known to concentrate in certain solid tumors. 13 First reports of Sestamibi uptake in benign and malignant lung tumors was in Now it is quite extensively used for the imaging Materials and Methods Whole-body planar and SPECT-CT Tc 99m-Sestamibi scans were performed on known cases of Myeloma in various stages of the disease from recently diagnosed to post chemotherapy and long term relapse. Where required, patients had follow-up scans to assess the progress of disease and change in scan pattern. The haematological parameters studied were CBC (Complete blood count) by automated 5 part cell counter, serum protein electrophoresis and serum B2 microglobulin and serum free light chains with kappa:lambda light chain ratio. Other biochemical tests like Liver function tests, Serum creatinine, Calcium were done. Additionally urine for Bence Jones Proteins was done in all patients. Procedure Whole body Tc99m Sestamibi Imaging (WBSI) : 20 mci of Tc99m Sestamibi was injected intravenously in a peripheral vein and whole-body scan was acquired after 5 minutes (Early WB scan) on a dual head Gamma camera using LEHR collimators. This was followed by SPECT-CT on a GE Hawkeye system, imaging in two bed positions covering the body area from mid-skull to base of thigh level. SPECT was acquired at 20 sec per step at 6 degree step-and-shoot method. CT scanning with low dose (2mA) helical CT is an integral part of the SPECT-CT scan and was acquired with the patient lying in the same position, immediately after the SPECT acquisition. This allows perfect superimposition of the SPECT and CT data to produce Fused images (Figure 1). Whole body planar scan was repeated at 2 3 hours after injection (Delayed scan). The scans were interpreted on high resolution colour monitors. Xeleris software was used for processing and display of SPECT-CT images, which allows simultaneous viewing of attenuation-corrected 802 JAPI september 2014 VOL. 62
3 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, SPECT images, the corresponding CT scan slice and Fused images where the tracer uptake in superimposed on the CT (anatomical) images (Figure 1). Reporting of the scans included description of the areas of abnormal tracer uptake and correlation with the CT images to exactly localize the sites of uptake. Additionally, the low dose CT scan images were also evaluated in the bone and soft tissue window settings to look for osteolytic bone lesions or other abnormalities. The results of scanning were compared with the clinical condition of the patient, haematological parameters, other radiological reports (where available) and any previous Sestamibi scan if available. Results (b) Fig. 2 : (a) Sestamibi Whole body planar scan anterior and posterior views. Note: The area of abnormal increased tracer uptake as indicated by the arrow may be difficult to appreciate on planar image. (b) The same lesion is much more clearly seen on SPECT slices (blue arrow) (a) From 2009 till May 2012, a total of 112 Whole body Sestamibi Scans were performed in 84 patients (46 Males; 38 Females). Out of these 24 (28.5%) were recently diagnosed cases (Pretherapy); 35 (41.7 %) were follow-up cases who had received Chemotherapy in the past (Post-therapy), there were 2 cases (2.3%) of Smouldering Myeloma, 4 cases (4.7 %) of Plasmacytoma, 13 cases (15.5 %) of MGUS and 3 cases (3.6%) were referred for a clinical suspicion of Myeloma (not biopsy confirmed). WBSI showed abnormal concentration of tracer in the bone marrow of patients of myeloma. The degree of uptake varied, from mild to moderate to intense and there were different patterns of tracer distribution seen (as discussed below). In addition, the low dose CT scan images of SPECT-CT showed changes ranging from the typical osteolytic lesions of myeloma, or sclerotic lesions or vertebral fractures in the bones in many patients. In effect this modality allowed two whole different types of skeletal survey of the patient. The Radionuclide distribution reflected the areas of abnormal increased metabolic activity (active disease) and the low dose CT images from base of skull to mid-thigh level provided an equivalent of a radiological skeletogram. The fusion of both this data provided an effective differentiation of the extent of myeloma bone disease. Certain Key Findings that were noted during this study are highlighted below 1. SPECT-CT images showed the areas of tracer uptake more prominently than the planar images. In most Sestamibi scans there is very prominent physiological uptake of tracer in hepatobiliary system and intestines, which causes relative reduction in contrast in marrow lesions in planar gamma camera images. In these cases particularly, the SPECT-CT images showed the abnormal areas of uptake more clearly (Figures 2a and b). 2. Anatomical localization of the areas of abnormal JAPI september 2014 VOL
4 32 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, 2014 Fig. 5 : The area of uptake highlighted by the blue arrow is physiological uptake in the muscle. It was falsely interpreted as a lesion on the planar image in Fig2a Fig. 3 : SPECT-CT images showed abnormal increased tracer uptake in many regions (marked by blue arrows) in bones though no lytic or sclerotic changes were evident radiologically ie on the CT images Fig. 6 : This image is the SPECT-CT image of the same patient in Fig 2a. SPECT-CT clearly demonstrates the area marked with arrow on planar image as a lytic lesion in the rib with an associated soft tissue also showing increased tracer activity Fig. 4 : Large osteolytic areas in sacrum and posterior iliac bones (blue arrow) seen on CT scan (left upper image) showed no abnormal tracer uptake (right upper and left lower) tracer uptake on the corresponding CT image showed typical punched-out osteolytic changes of myeloma in many cases. However very often, though there was abnormal increased MIBI concentration in the bone, the CT images showed no obvious lytic or sclerotic changes (Figure 3). This is because metabolic changes on radionuclide scanning become apparent much earlier than radiological changes. 3. Conversely, in many patients the CT images showed widespread osteolytic areas in bones but no abnormal tracer concentration in these lesions (arrow marked areas in Figure 4). These were all in post-treatment patients where radiological changes persisted even though lesions had become metabolically negative. 4. Sometimes areas of apparently abnormal tracer uptake noted on the planar Sestamibi images, on correlation with the anatomical image on fused 804 JAPI september 2014 VOL. 62
5 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, (a) (a) (b) Fig. 7 : (a) Whole body Mibi scan- showed abnormal tracer uptake in right rib posteriorly, left ischium and intense uptake in left leg (blue arrow). (b) SPECT- CT images demonstrate a large soft tissue mass in leg. Additionally on SPECT-CT another lesion was detected in a cervical lymph node, which was not evident on the planar image. Both these lesions were bopsied and showed myelomatous deposits SPECT-CT images, were found to be areas of physiological uptake most often physiological muscle uptake (Figure 5), a thyroid lobe, or gut activity. Hence addition of correlative CT scan helped reduce false positives. 5. In addition to abnormal Sestamibi distribution in bone marrow, the low-dose scan helped identify other associated skeletal changes such as vertebral (b) Fig. 8 : (a) The two images on the left show FDG PET-CT scan images of a recently diagnosed case of Multiple myeloma with multiple hyperactive lesions(marked by arrows) in vertebrae, chest and pelvic bones. (b) On the right side are the WBSI of same patient within the same week as the PET scan showing areas of active disease in the same locations fractures or abnormal associated soft tissue lesions (Figure 6). 6. The planar WBSI occasionally detected disease in soft tissue such as lymph nodes, in addition to bone disease. Occasionally active disease was seen in the peripheries, in clinically unsuspected sites, and in those areas not routinely covered in radiological assessments (Figure 7). 7. In cases where FDG PET scan was also done, there was good correlation with findings on both scans. The lesions were definitely more intense and well defined on the FDG PET scan (Figure 8a) in most cases, but on careful inspection most of the areas of abnormal uptake could be also visualized on Mibi SPECT-CT (Figure 8b). This is due to the JAPI september 2014 VOL
6 34 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, 2014 Fig. 9 : MRI scan showed scattered areas of altered marrow signal in multiple vertebrae. Sestamibi SPECT-CT images showed increased tracer uptake in corresponding multiple vertebrae (a) (b) Fig. 10 : (a) FDG PET-CT images done 1 week back showed diffusely increased tracer uptake in the same regions, but were reported as normal - probably due to the homogeneity of uptake. (b) Wholebody Mibi scan and SPECT-CT images showing diffusely increased tracer uptake in vertebrae, pelvic bones, upper ends of femurs, ribs and skull, which were proven on biopsy as myeloma intrinsic higher resolution ability of PET imaging and the better resolution of the CT on the PET-CT scanner, as compared to the low dose CT scanner of SPECT-CT. 8. There was also good correlation between WBSI and MRI of patients with newly diagnosed myeloma (Figure 9). An exception to note In an isolated case (Figure 10) where we found diffusely increased abnormal concentration of MIBI in a newly diagnosed case of Myeloma (Biopsy proven), the FDG PET-CT scan done elsewhere had been (falsely) reported as Normal. On retrospective evaluation of the PET images it was noticed that there was in fact, diffuse uptake of FDG in the marrow. This is just to highlight that occasionally a very diffuse, homogenous uptake of FDG in marrow could be difficult to differentiate from the normal pattern of physiological FDG uptake. 22 FDG uptake in lesions is also significantly linked to blood glucose profile, and this could have been one of the contributory factors for relatively low uptake in lesions. Analysis of Pre- therapy Patients All (100%) newly diagnosed myeloma patients, scanned prior to the commencement of chemotherapy showed abnormal concentration of Tc Sestamibi in the bones / marrow. Three basic scan patterns (Figure 11) were observed. 1. Diffusely increased tracer uptake in skeleton 806 JAPI september 2014 VOL. 62
7 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, Fig 11: Three basic patterns of tracer distribution seen in Pre-therapy patients of myeloma Multifocal lesions 33% Diffusely increased Uptake 59% Osteolytic areas but lesser than areas of uptake 46% Showed Osteolytic areas in all 25% Diffuse + Focal lesions 8% Chart 1 : Percentage of patients showing the various patterns of tracer uptake in myeloma (59% of patients) - uniformly increased uptake especially in all vertebrae, bilateral pelvic bones, bilateral ribs and chest bones and prominent uptake in upper ends of femurs and humerii. Occasionally diffuse increased uptake in skull bones was seen. 2. Multiple discrete focal areas of increased tracer uptake (33% cases) 3. Mixed pattern of diffuse and additional focal areas of uptake (8% of cases) - in addition to the diffuse uptake in marrow, there were some areas showing markedly increased focal uptake, more intense than other areas. Chart 1 below demonstrates the relative occurrence of these 3 patterns Analysis of the low-dose CT scan images of these Chart 2 : Evaluation of low dose CT images in Pretherapy patients Percentage of cases showing osteolyic changes as compared to areas of abnormal Mibi uptake pre-therapy patients revealed three main categories of findings (Chart 2) 71% (46% +25%) cases showed presence of osteolytic bone lesions (often lesser than the extent of Mibi uptake) and 29% showed no osteolytic changes in spite of the abnormal Mibi uptake. Analysis of Post Therapy Patients No osteolytic areas 29% 35 Follow-up cases of myeloma, who had received chemotherapy with or without bone marrow transplant in the past (ranging from 3 months to 7 years post therapy) were scanned. Of these, 18 patients (51.4%) were clinically stable (in Remission) with plasma JAPI september 2014 VOL
8 36 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, % 45.0% 40.0% 35.0% 30.0% 25.0% 20.0% 15.0% 10.0% 5.0% 0.0% Follow-Up Patients in Clinical Remission Chart 3a : Patterns of Sestamibi uptake in clinically stable patients - correlation of tracer uptake and osteolytic areas seen on CT 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 44.4% Osteolytic Areas - No Uptake 16.7% No Osteolytic Areas - No Uptake 38.9% Osteolytic Areas - Minimal Uptake Follow up Patients in Clinical Recurrence 52.9% 41.2% Mixed Pa ern Uptake areas >> Osteolytic areas 5.9% Uptake areas = Osteolytic areas Chart 3b : Patterns and combinations of Sestamibi uptake in clinically recurrent cases of myeloma correlation of tracer uptake and osteolytric areas seen on CT protein levels and B2 Microglobin levels in the acceptable range; 17 (48.6%) presented with clinical Recurrence with abnormal biochemical markers, with or without symptoms. The aim of the scans was to detect presence, and assess the extent of recurrent disease. Of the 18 patients in Clinical Remission (Chart 3a) a. 11 (61%) showed no abnormal concentration of Sestamibi. Considering that all these patients had active bone disease in the past, CT images showed persistent osteolytic lesions in a large proportion 8 of these patients. However these osteolytic bone lesions were negative for Mibi uptake (metabolically inactive). 3 patients showed neither abnormal MIBI uptake nor any osteolytic bone lesions b. 7 patients (39%) showed osteolytic areas with some areas of minimally increased tracer uptake. Of the 17 Clinically Recurrent patients (Chart 3b) All (100%) showed abnormal tracer concentration. However there were various combinations of scan findings in these patients as demonstrated in the chart 3b. 9 patients (53%) showed multiple osteolytic areas - some showing areas of abnormal uptake and some showing no uptake and in addition some areas of abnormal uptake where no lytic lesions were seen (Mixed pattern). 7 patients showed multiple abnormal areas of uptake, many of which revealed no corresponding lytic areas and some showed osteolytic lesions (ie Areas of Uptake > osteolytic areas). In 1 patient, all the areas of tracer uptake correlated to lytic lesions. In 2 cases where CT scan findings of osteolysis seemed clinically very suspicious, the lesions were actually biopsied and revealed absence of active disease (fibrosis) in osteolytic areas showing no tracer uptake (Figure 12). Plasmacytoma Patients (a) (b) (c) Fig. 12 : (a and b) Large osteolytic areas in bilateral iliac bones (marked by arrows in the upper images) showing no increased tracer uptake (lower images) To rule out possibility of the lesions in iliac bones being false negative for MIBI uptake a CT-guided biopsy was done from these iliac lesions. Histopathology. (c) confirmed absence of myeloma in these lesions and showed only fibrous tissue 4 patients diagnosed as Plasmacytoma clinically and by radiology, were referred for scan. The aim was to assess the metabolic activity of the lesion and rule out possibility of multiple / metastatic lesions. The site of the plasmacytoma was in the Sternum in 3 cases and in the vertebra in one. All the patients 808 JAPI september 2014 VOL. 62
9 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, demonstrated intense uptake of Tc Sestamibi in the primary lesion with associated osteolytic changes seen on CT images (Figure 13). In one of the 3 cases, additional smaller areas of abnormal tracer uptake were detected on scan. (Figure 14). This patient was given radiotherapy to the sternal lesion and after 3 months referred for scan again to assess the response to treatment. The follow-up scan showed reduction in the intensity of the sternal lesion; however multiple other marrow lesions had developed elsewhere in the body. 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% Fig. 13 : Whole body scan showing intense tracer uptake in the sternal region (arrow marked) No metastatic lesions seen in rest of the body. SPECT-CT images (lower) show a large, expansile osteolytic lesion in the sternum showing increased tracer uptake 0.0% No abnormal Uptake Some mild diffuse uptake Chart 4 : Pattern of tracer uptake in MGUS patient MGUS Patients Diffuse increased uptake 13 patients of Monoclonal gammopathy with no identifiable radiological lesions and biopsy negative for myeloma were studied. Of these 9(69.2%) showed no abnormal uptake of Tc Sestamibi in the skeleton. 2 patients (15.3%) showed very mild diffusely increased tracer uptake in bones with no osteolytic areas seen and 2 (15.3%) showed prominent diffusely increased tracer uptake in the marrow but no osteolytic areas (Chart 4). One of the patients with prominent diffuse marrow uptake was re-biopsied but no active myeloma disease was seen and histopathology showed reactive marrow only. Patients with Follow-up Scans (a) (b) Fig. 14 : (a) Scan at the time of diagnosis showed intense tracer uptake in the sternal lesion (curved arrow). There was an additional smaller lesion in lateral end of left clavicle (straight arrow). (b) Follow up scan after radiotherapy to the sternal lesion showed significant regression of the sternal uptake but multiple other smaller areas of abnormal tracer uptake due to metastatic disease in other bones Of our total series of 84 patients, 23 patients had follow-up scans. Nineteen patients had a single follow up, 3 had two follow-up scans and 1 patient had three follow up scans. At each point of time there was found to be good correlation between the JAPI september 2014 VOL
10 38 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, 2014 (a) (b) Fig 15 : (a) In a case of myeloma post chemotherapy and clinically and biochemically in remission in Feb 2010, the whole body scan showed no abnormal tracer uptake. (b): In 2012 patient had body ache and anaemia. WBSI showed diffusely increased tracer uptake in vertebrae, sternum, scapulae, ribs, bilateral pelvic bones, upper ends of humerii and femurs and left upper tibia. She was found to have abnormal rise in plasma protein and B2 Microglobin levels and biopsy confirmed recurrent disease Biochemical parameters of the patient and the scan findings and Tc Sestamibi scan was able to provide indication about the extent of disease. Figure 15 gives an illustrative example of detection of recurrent disease by WBSI. Discussion The physiological uptake of Tc-Sestamibi by multiple organs causes significant background activity of tracer and on planar Gamma camera scanning this makes it difficult to detect lesions. This is probably the main reason Tc Sestamibi never became popular as a whole body tumor-imaging agent. However in our study we found several factors that have emerged from the development of technology, that make WBSI a viable option. The intrinsically higher resolution of newer gamma cameras, addition of SPECT and now the incorporation of inbuilt CT scanner in SPECT-CT imaging adds two major benefits (a) use of attenuation correction in SPECT-CT dramatically increases sensitivity (Figure 2) (b) Radiological image corregistration increases Specificity by distinguishing abnormal vs. physiological uptake and allows further characterization of the lesions (Figure 5). Apart from a whole body MIBI distribution, the WBSI also incorporates a whole-body low-dose CT scan. Low-dose CT scans are better than plain X-rays for detection of osteolytic myeloma bone lesions (23) and there are recent reports regarding use of whole body low dose CT scans for assessment of myeloma extent. 24 However, metabolic imaging becomes positive earlier than X-ray changes, and as seen in our series, in many newly diagnosed patients, many areas of early active disease which showed abnormal MIBI uptake were not apparent on X-ray / CT due to absence of lytic / sclerotic changes (Figure 3 and Table 2). Therefore, the use of only X-rays or low-dose CT scan for initial staging assessment may be questionable. Moreover in post-therapy follow-up patients, WBSI can differentiate old burnt-out osteolytic lesions (which may persist for years despite therapy 25 and are inactive) from those that are active (Figure 12). FDG PET-CT which combines metabolic imaging with high resolution CT scanning is emerging as the ideal modality for imaging myeloma. Its advantages over MRI are better body coverage, and more specificity in post treatment evaluation. Multiple studies have now proven the benefit of FDG PET-CT scanning for assessment of myeloma extent Where not available, we found that MIBI imaging to be a useful surrogate since patterns of disease extent were similar on both these scans. MRI is excellent for detection of areas of altered marrow signal and is a very useful tool at initial diagnosis of disease. A comparative study by Fonti et al 26 showed good correlation between detection of myeloma lesions in spine and pelvis by both MRI and Sestamibi scan. In the recently diagnosed cases in our series, where available, WBSI compared very well with MRI findings (Figure 9). MRI has the distinct advantage of better anatomical detailing of bone and soft tissue lesions and can define bone masses causing pressure effects and identify any neurologically critical lesions. The only major advantage of WBSI at diagnosis over MRI would be the wider whole-body coverage of WBSI as compared to regional MRI, with the occasional chance of missing out on peripheral lesions (Figure 7). 810 JAPI september 2014 VOL. 62
11 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, However in the post treatment scenario, the specificity of MRI marrow changes is somewhat reduced since it may not be able to differentiate active disease from reparative marrow changes. 23 WBSI in this setting was found to be useful to pick out only the areas of active disease (Table 3). The Durie Salmon PLUS staging system for myeloma integrates the more sensitive techniques like MRI, CT and PET-CT into its classification system. 30 However, the current IMWG (International Myeloma Working Group) and NCCN guidelines do not recommend the routine use of radiological imaging other than X-Ray skeletal survey, except in certain situations. However, the issue is whether the emphasis on X-ray skeletal survey for detection of bone disease in myeloma is appropriate, as it can miss lesions till 30% of the bone mass is destroyed and its high false negative rate of 30-70%. 23,24,31 Moreover for follow-up of patients, X-ray cannot be reliable for assessment of response to therapy as the lytic bone lesions seldom show evidence of healing. 25 Also, skeletal survey finds no place in the ISS score which looks at the extent of the disease biochemically. If the Durie Salmon scoring were to be considered, IMWG mentions that bone lesions need to be treated even if the patient is asymptomatic, which means that a sizeable patients (with false negative X-ray survey) will not be treated due to the inherent deficiency of this modality. In clinical practice, biochemical markers are usually used as follow-up indicators for disease recurrence. In our study we found that all (100%) follow-up patients with clinical suspicion of relapse showed positive WBSI scan (Table 3). In this category of patients mixed pattern of disease is commonly seen with active lesions with or without osteolytic changes interspersed with old non-osteolytic lesions. A typical bone marrow examination from the posterior superior iliac spine may be negative due to patchy marrow involvement of myeloma. WBSI may be useful to detect and guide the exact areas of active disease to decide biopsy site WBSI is particularly useful in cases which present as plasmacytomas. It is known that after local radiotherapy many of plasmacytoma patients return with multiple myeloma since the smaller lesions were missed by conventional radiology at initial screening. 32,33 Detection of additional areas of active disease at the time of diagnosis would help restage the disease and prompt initiation of systemic therapy early along with locoregional therapy of the plasmacytoma mass (Figure 12). Conclusion WBSI with SPECT-CT is a very useful and easily available technique for imaging of Myeloma. It has good sensitivity in detection of diffuse and focal disease - with SPECT CT remarkably improving the sensitivity. At any given clinical point, it demonstrates the extent of disease and distinguishes Active vs. Inactive lesions. Most importantly it is a cost-effective study, with distinct advantages over conventional radiology. In the absence of a PET-CT, it is an effective tool for assessing myeloma disease extent at diagnosis and follow-up. References 1. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005;16: Blade J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years: report of 10 cases and review of the literature. Arch Intern Med 1996;156: Edgardo J.C.Angtuaco, Anthanasios BT Fassas, Ronald Walker, Rajesh Sethi, Bart Barlogie, Multiple Myeloma: Clinical Review and Diagnostic Imaging, Radiology 2004;231: Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005;16: Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma Br J Haematol 2006;132: Mulligan ME. Skeletal abnormalities in multiple myeloma. Radiology 2005;234: ;author reply Gleeson TG, Moriarty J, Shortt CP, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 2009;38: C. F. Healy, J. G. Murray, S. J. Eustace, J.Madewell, P. J. O Gorman, and P. O Sullivan MultipleMyeloma:A Review of Imaging Features and Radiological Techniques Bone Marrow research 2011;ArticleID Ludwig H, Kumpan W, Sinzinger H. Radiography and Bone Scintigraphy in multiple myeloma: a comparative analysis. British Jornal of Radiology 1982;55: Dimopoulos MA et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma, Leukemia 2009; Durie BGM, Waxman AD, D Agnolo A, Williams C. Whole-body F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43: Backus et al. Am J Physiol 1993;265:C Maffioli L,Steevens J,Pauwels E,Bombardieri E. Applications of 99mTcsestaMIBI in oncology. Tumori 1996;82: Hassan et al, Uptake and kinetics of Tc 99m-hexacis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989;14: Tirovola Eb et al The use of 99mTc-MIBI scanning in multiple myeloma. Br J Cancer 1996;74: Pace L, Catalano L, Pinto A et al, Different Patterns of technetium-99m Sestamibi uptake in multiple myeloma. Eur J Nucl Med 1998;25: Use of 99mTc-Sestamibi Scintigraphy in Multiple Myeloma, Letter to Editor, Pace L, Salvatore M, Vecchio S, JNM 2006;47: Balleari E, Villa G, Garre S, et al, Technitium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies : a useful tool for identification and follow-up of myeloma bone disease. Haematologica 2001;86:78-84 JAPI september 2014 VOL
12 40 Journal of the association of physicians of india vol 62 published on 1st of every month 1st september, Nandurkar D, Kalff V, Turlakow A, Spencer A, Bailey MJ,Kelly MJ. Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake. Eur J Haematol 2006;76: Pace L, Catalano L, Del Vecchio S, De Renzo A, Fonti R, Salvatore B et al. Washout of sestamibi in predicting response to chemotherapy in patients with multiple myeloma. Q J Nucl Med Mol Imaging 2005;49: Martin G Martin, Maria S, Maria V,et al, Baseline Tc99m-MIBI scanning predicts survival in multiple myeloma and helps differentiate this disease from monoclonal gammopathy of unknown significance. Haematologica 2005;90: Ayda M et al, Technitium 99m-MIBI Versus Fluorine 18-FDG in Diffuse Multiple Myeloma. Journal of Nuclear Medicine 1997;38: CF Healy, JG Murray, SJ Eustace, J Madewell, PJO Gorman, P O Sullivan MultipleMyeloma:A Review of Imaging Features and Radiological Techniques Bone Marrow research 2011;ArticleID Princewill K, Kyere S, Awan O, Mulligan M, Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey. Cancer Invest 2013;31: doi: / Epub2013Feb Edelstyn GA etal, The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol 1967;18: Rosa Fonti, Barbara Salvatore et al, 18-FDG PET-CT, Tc99m MIBI and MRI in evaluation of Pateints with Multiple Myeloma. J Nucl Med 2008;49: Christopher J Hanrahan, Carl R Christensen, Julia R Crim, Current Concepts in the Evaluation of Multiple Myeloma with MR Imaging and FDG PET/CT. RadioGraphics 2010;30: Durie BG, Waxman AD, D_Agnolo A, Williams CM. Whole-bodyF18- FDG PET identifies high-risk myeloma. J Nucl Med 2002;43: Breyer III RJ, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 2006;35: B.G.M. Durie, The role of Anatomic and Functional Staging in Myeloma: description of Durie/Salmon PLUS staging system. European Journal of Cancer 2006;42: International Myeloma Foundation: International Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma, Wahlin A, Holm J, et al, Evaluation of serial bone X-ray examination in Multiple myeloma. Acta Med Scand 1982;212: Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary Plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000;96: JAPI september 2014 VOL. 62
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7
Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Authors Ronald C. Walker 1,2, Tracy L. Brown 3, Laurie B. Jones-Jackson
More informationA Diagnostic Chest XRay: Multiple Myeloma
Daniela Marinho Tridente, VI FCMSCSP October 2013 A Diagnostic Chest XRay: Multiple Myeloma Daniela Marinho Tridente, VI FCMSCSP Our Learning Agenda Introduction of our patient His imaging data and findings
More informationTechnetium-99m Sestamibi in Multiple Myeloma
Journal of the Egyptian Nat. Cancer Inst., Vol. 1, No. 1, March: 87-93, 2002 Technetium-99m Sestamibi in Multiple Myeloma RAFAT A. SABER, M.D. Radiotherapy and Nuclear Medicine Dept., Assiut University.
More informationThings You Don t Want to Miss in Multiple Myeloma
Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University
More informationMultiple Myeloma Patient s Booklet
1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple
More informationUNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
More informationMultiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma.
Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma. The intent is to positively identify patients with active or
More informationMultiple Myeloma. Abstract. Introduction
Multiple Myeloma Abstract Multiple Myeloma is a plasma cell cancer that causes an overproduction of plasma cells. Multiple Myeloma is a difficult disease to diagnosis because symptoms might not be present
More informationIn Practice Whole Body MR for Visualizing Metastatic Prostate Cancer
In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer Prostate cancer is the second most common cancer in men worldwide, accounting for 15% of all new cancer cases. 1 Great strides have
More informationNew diagnostic criteria for myeloma
New diagnostic criteria for myeloma Dr Guy Pratt Senior Lecturer/Honorary Consultant Haematologist University of Birmingham/Heart of England NHS Trust International Myeloma Working Group (IMWG) define
More informationPET/CT in Breast Cancer
PET/CT in Breast Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria Overview Introduction Locorregional
More informationMULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology
MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data
More informationInformation Pathway. Myeloma tests and investigations. Paraprotein measurement
Information Pathway Myeloma UK Broughton House 31 Dunedin Street Edinburgh EH7 4JG Tel: + 44 (0) 131 557 3332 Fax: + 44 (0) 131 557 9785 Myeloma Infoline 0800 980 3332 www.myeloma.org.uk Charity No. SC
More informationFalse positive PET in lymphoma
False positive PET in lymphoma Thomas Krause Introduction and conclusion 2 3 Introduction 4 FDG-PET in staging of lymphoma 34 studies with 2227 Patients CT FDG-PET Sensitivity 63 % 89 % (58%-100%) (63%-100%)
More informationMalignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
More informationPET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationRadiologic Diagnosis of Spinal Metastases
September 2002 Radiologic Diagnosis of Spinal Metastases Natalie J. M. Dailey, Harvard Medical Student Year III Our Patient s Presenting Story 70 year old male Presents to the hospital for laparascopic
More informationTreating Thyroid Cancer using I-131 Maximum Tolerable Dose Method
Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method Christopher Martel, M.Sc., CHP Lisa Thornhill,, NRRPT, RT(NM) Boston University Medical Center Thyroid Carcinoma New cases and deaths in
More informationPET/CT: Basic Principles, Applications in Oncology
PET/CT: Basic Principles, Applications in Oncology Mabel Djang, HMS III Overview PET Basics and Limitations PET/CT - Advantages and Limitations Applications of PET/CT in oncology Summary 2 Principles of
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationHERC Coverage Guidance Advanced Imaging for Staging of Prostate Cancer Disposition of Public Comments
Table of Contents Commenters... 1 Public Comments... 2 References Provided by Commenters... 6 Commenters Identification Stakeholder A Medical Imaging & Technology Alliance (MITA), Arlington, VA [Submitted
More informationMyeloma pathways to diagnosis UCLP audit
Myeloma pathways to diagnosis UCLP audit Dr Neil Rabin Consultant Haematologist University College London Hospitals & North Middlesex University Hospital Myeloma Clinical Features Bone pain (70%) High
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationMultiple Myeloma Understanding your diagnosis
Multiple Myeloma Understanding your diagnosis Multiple Myeloma Understanding your diagnosis When you first hear that you have cancer you may feel alone and afraid. You may be overwhelmed by the large amount
More informationchronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
More informationMultiple Myeloma with Pathologic Fracture: the Role and Treatment Consideration of RT
Multiple Myeloma with Pathologic Fracture: the Role and Treatment Consideration of RT Case Number: RT2009-37(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor Purpose: to present
More informationPET. Can we afford PET-CT. Positron annihilation. PET-CT scanner. PET detection
PET-CT Can we afford PET-CT John Buscombe New technology Combines functional information-pet anatomical information-ct Machine able to perform both studies in single imaging episode PET imaging depends
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Breast cancer Faculty of Clinical Radiology www.rcr.ac.uk Contents Breast cancer 2 Clinical background 2 Who
More informationSOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008
Introduction This disease site includes the following three malignancies: multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia. See pages 4 and 5 for descriptions of the latter two diseases.
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationElements of PET/CT Reporting
Elements of PET/CT Reporting 1. Clinical History a. Indication i. tumor type ii. abnormality to be evaluated iii. specific clinical question b. Relevent history i. biopsy results ii. chemotherapy iii.
More informationBackground Information Myeloma
Myeloma FAST FACTS Myeloma, also known as multiple myeloma, is a type of cancer that develops from plasma cells which originate in the bone marrow 1 Myeloma is the second most common type of blood cancer
More informationLYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis
LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the
More informationNON SECRETORY MULTIPLE MYELOMA A CASE REPORT
NON SECRETORY MULTIPLE MYELOMA A CASE REPORT Golwilkar A.,*Saluja R., Mehendale A. and Jalnapurkar N. Department of Histopathology, Golwilkar Metropolis Health Services (India) Pvt Ltd *Author for Correspondence
More information.org. Metastatic Bone Disease. Description
Metastatic Bone Disease Page ( 1 ) Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer
More informationSodium Fluoride PET/CT Bone Imaging: Theory and Practice
Sodium Fluoride PET/CT Bone Imaging: Theory and Practice George Segall, M.D. Stanford University Why F-18 Fluoride? Faster Higher Resolution Anatomic Correlation Chemiadsorption Hydroxyapatite Ca10(PO4)6(OH)2
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationCrosswalk for Positron Emission Tomography (PET) Imaging Codes G0230 G0030, G0032, G0034, G0036, G0038, G0040, G0042, G0044, G0046
Positron Emission Tomography (PET) CPT to HCPCS Level Crosswalk Changes below from CMS Change Request 3741 Transmittals 518 & 31 published on April 1, 2005; mplementation of CPT codes are effective January
More informationCPT CODE PROCEDURE DESCRIPTION. CT Scans 70450 CT HEAD/BRAIN W/O CONTRAST 70460 CT HEAD/BRAIN W/ CONTRAST 70470 CT HEAD/BRAIN W/O & W/ CONTRAST
CPT CODE PROCEDURE DESCRIPTION CT Scans 70450 CT HEAD/BRAIN W/O CONTRAST 70460 CT HEAD/BRAIN W/ CONTRAST 70470 CT HEAD/BRAIN W/O & W/ CONTRAST 70480 CT ORBIT W/O CONTRAST 70481 CT ORBIT W/ CONTRAST 70482
More informationNM- Nuclear Medicine
NM- Nuclear Medicine CODE DESCRIPTION 78000 Thyroid uptake; single determination 78001 Thyroid uptake; multiple determinations 78003 Thyroid uptake; stimulation, suppression or discharge 78006 Thyroid
More informationA Clinical Primer. for Managed Care Stakeholders
reviews therapy Diagnosing, Staging, and Treating Multiple Myeloma: A Clinical Primer for Managed Care Stakeholders by Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders
More informationMULTIPLE MYELOMA WITH BILATERAL HUMERUS LOCATION CASE REPORT
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2013 vol. 117, no. 1 SURGERY CSE REPORTS MULTIPLE MYELOM WITH ILTERL HUMERUS LOCTION CSE REPORT O. lexa,. Veliceasa University of Medicine and Pharmacy Grigore T. Popa
More informationMultiple Myeloma. This reference summary will help you understand multiple myeloma and its treatment options.
Multiple Myeloma Introduction Multiple myeloma is a type of cancer that affects white blood cells. Each year, thousands of people find out that they have multiple myeloma. This reference summary will help
More informationDisease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
More informationMonoclonal Gammopathy of Undetermined Significance (MGUS) Facts
Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts Normal plasma cells (a type of white blood cell) produce antibodies (also known as immunoglobulins) which help fight infection. Each type
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationMultiple Myeloma Workshop- Tandem 2014
Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationCT-guided Biopsy of Focal Lesions in Patients with Multiple Myeloma May Reveal New and More Aggressive Cytogenetic Abnormalities
AJNR Am J Neuroradiol 22:781 785, April 2001 CT-guided Biopsy of Focal Lesions in Patients with Multiple Myeloma May Reveal New and More Aggressive Cytogenetic Abnormalities Ramesh Avva, Rudy L. Vanhemert,
More informationCase Report: Whole-body Oncologic Imaging with syngo TimCT
Case Report: Whole-body Oncologic Imaging with syngo TimCT Eric Hatfield, M.D. 1 ; Agus Priatna, Ph.D. 2 ; John Kotyk, Ph.D. 1 ; Benjamin Tan, M.D. 1 ; Alto Stemmer 3 ; Stephan Kannengiesser, Ph.D. 3 ;
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationSolitary Plasmocytoma of Bone
18 F-FDG PET/CT in Myeloma with Presumed Solitary Plasmocytoma of Bone CRISTINA NANNI 1, DOMENICO RUBELLO 2, ELENA ZAMAGNI 3, PAOLO CASTELLUCCI 1, VALENTINA AMBROSINI 1, GIANCARLO MONTINI 1, MICHELE CAVO
More informationMetastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female
More informationOncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control
Oncology Objectives Describe the etiology and pathophysiological mechanisms of cancer Discuss medical and family history findings relevant to cancer Identify general signs and symptoms associated with
More informationI've Just Been Diagnosed. with Multiple Myeloma, What s Next?
I've Just Been Diagnosed with Multiple Myeloma, What s Next? Table of Contents Message from a Survivor Introduction What is Multiple Myeloma? What Causes Multiple Myeloma? Genes & Multiple Myeloma What
More information2011 Radiology Diagnosis Coding Update Questions and Answers
2011 Radiology Diagnosis Coding Update Questions and Answers How can we subscribe to the Coding Clinic for ICD-9 guidelines and updates? The American Hospital Association publishes this quarterly newsletter.
More informationAggressive lymphomas. Michael Crump Princess Margaret Hospital
Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More informationManagement of spinal cord compression
Management of spinal cord compression (SUMMARY) Main points a) On diagnosis, all patients should receive dexamethasone 10mg IV one dose, then 4mg every 6h. then switched to oral dose and tapered as tolerated
More informationA Focus on Multiple Myeloma
A Focus on Multiple Myeloma Guest Expert: Madhav Dhodapkar, MD Professor of Hematology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr.
More informationPET/CT in Lymphoma. Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto
PET/CT in Lymphoma Ur Metser, M.D. Division Head, Molecular Imaging Joint Department of Medical Imaging, UHN- MSH- WCH University of Toronto Outline 1. Introduction: PET/CT, how does it work? 2.Current
More informationPositron Emission Tomography - For Patients
Positron Emission Tomography - For Patients A physician s written order is required for any PET-CT tests. How should I prepare for my PET-CT? PET-CT is more complicated than most other tests you may be
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationRadiotherapy in Plasmacytoma and Myeloma. David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015
Radiotherapy in Plasmacytoma and Myeloma David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015 Contents Indications for radiotherapy: Palliation in Multiple Myeloma Solitary Bone Plasmacytoma
More informationCHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
More informationCPT Radiology Codes Requiring Review by AIM Effective 01/01/2016
CPT Radiology Codes Requiring Review by AIM Effective 01/01/2016 When a service is authorized only one test per group is payable. *Secondary codes or add-on codes do not require preauthorization or separate
More informationPathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France Bone metastases 70 % of prostate and breast cancers 30 % of lung, bladder and thyroid
More informationLow-dose CT Imaging. Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital
Lung Cancer Screening with Low-dose CT Imaging Edgar Fearnow, M.D. Section Chief, Computed Tomography, Lancaster General Hospital Despite recent declines in the incidence of lung cancer related to the
More informationDiagnostic Imaging Prior Review Code List 3 rd Quarter 2016
Computerized Tomography (CT) Abdomen 6 Abdomen/Pelvis Combination 101 Service 74150 CT abdomen; w/o 74160 CT abdomen; with 74170 CT abdomen; w/o followed by 74176 Computed tomography, abdomen and pelvis;
More informationThomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia. Meet Mr. S
Thomas de los Reyes PGY 1 Department of Urologic Sciences University of British Columbia Meet Mr. S 74 M admitted for back pain X-ray: sclerotic lesions along spine PSA 800 Nuclear Medicine Bone Scan 1
More informationPET/CT-MRI First clinical experience
20 th April 2013, Barcelona, Sp PET/CT-MRI First clinical experience Philippe Appenzeller, MD Staff Radiologist and Nuclear Medicine Physician Department Medical Imaging, University Hospital Zurich PET/CT-MR
More informationThe Lewin Group undertook the following steps to identify the guidelines relevant to the 11 targeted procedures:
Guidelines The following is a list of proposed medical specialty guidelines that have been found for the 11 targeted procedures to be included in the Medicare Imaging Demonstration. The list includes only
More informationCase Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor
Renal Cell Carcinoma of the Left Kidney Post Radical Surgery with pt4 Classification with Multiple Lung and Single Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-124(M)
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationSalute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine
Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Salute to Dr. Saul Hertz Diagnostic and Therapeutic Uses of Radioiodine Douglas Van Nostrand, MD, FACP, FACNM Director, Nuclear Medicine
More informationSpatial mismatch in CT-defined vs. NaF PET-defined lesions: implications for diagnostic bone biopsies
Spatial mismatch in CT-defined vs. NaF PET-defined lesions: implications for diagnostic bone biopsies Stephanie Harmon, Song Chen, Peter Ferjancic, Timothy Perk, Michael Tuite, and Robert Jeraj University
More informationMalignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
More informationThe Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline Introduction ASCO convened an Update Committee to review and update the 2002 recommendations for the role of bisphosphonates
More informationTable of Contents Accelerate Your Research Introduction I. From the Real World to the Lab II. Research Challenges III. How Can Conversant Bio Help?
Table of Contents Accelerate Your Research 2 Introduction 3 I. From the Real World to the Lab 4 A. Diagnosing Multiple Myeloma 4 1. Lab Tests 4 2. Bone Marrow Exams 6 3. Imaging Studies 7 B. Subtypes of
More informationAI CPT Codes. x x. 70336 MRI Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)
Code Category Description Auth Required Medicaid Medicare 0126T IMT Testing Common carotid intima-media thickness (IMT) study for evaluation of atherosclerotic burden or coronary heart disease risk factor
More informationThymus Cancer. This reference summary will help you better understand what thymus cancer is and what treatment options are available.
Thymus Cancer Introduction Thymus cancer is a rare cancer. It starts in the small organ that lies in the upper chest under the breastbone. The thymus makes white blood cells that protect the body against
More informationComputed Tomography, Head Or Brain; Without Contrast Material, Followed By Contrast Material(S) And Further Sections
1199SEIU BENEFIT AND PENSION FUNDS High Tech Diagnostic Radiology and s # 1 70336 Magnetic Resonance (Eg, Proton) Imaging, Temporomandibular Joint(S) 2 70450 Computed Tomography, Head Or Brain; Without
More informationBone Disease in Myeloma
Bone Disease in Myeloma Washington, DC August 8, 2009 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma Vascular Cytokines
More informationCMS Limitations Guide Mammograms and Bone Density Radiology Services
CMS Limitations Guide Mammograms and Bone Density Radiology Services Starting July 1, 2008, CMS has placed numerous medical necessity limits on tests and procedures. This reference guide provides you with
More informationHOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1
HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 This document describes the minimally required staging and evaluation procedures and response criteria that will be applied in all
More informationBone Disease in Plasma. Cell Dyscrasias
Bone Disease in Plasma July 2004 Cell Dyscrasias Courtesy of Dr. Ferris Hall Sarah Billmeier Harvard Medical School Year III Objectives Characterization of the plasma cell neoplasms Radiologic work up
More information11 The Skeletal System
209 The Skeletal System Bone scanning evaluates bone physiology and skeletal anatomy and is one of the most common applications of nuclear imaging. SPECT provides improved sensitivity and even greater
More informationMRI of Bone Marrow Radiologic-Pathologic Correlation
MRI of Bone Marrow Radiologic-Pathologic Correlation Marilyn J. Siegel, M.D. Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, MO and Visiting Scientist, AFIP, Washington,
More informationGeneral Nuclear Medicine
Scan for mobile link. General Nuclear Medicine Nuclear medicine imaging uses small amounts of radioactive materials called radiotracers that are typically injected into the bloodstream, inhaled or swallowed.
More informationCanine Lymphoma Frequently Asked Questions by Pet Owners
Canine Lymphoma Frequently Asked Questions by Pet Owners What is lymphoma? The term lymphoma describes a diverse group of cancers in dogs that are derived from white blood cells called lymphocytes. Lymphocytes
More informationPost-PET Restaging Cancer Form National Oncologic PET Registry
Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer
More informationTABLE OF CONTENTS. Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data
Instructions for Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data (Form 2016) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Multiple Myeloma /
More informationExtramedullary Plasmacytoma
Extramedullary Plasmacytoma Carole Fakhry MD MPH The Milton J. Dance, Jr. Head and Neck Center at GBMC HEAD AND NECK GRAND ROUNDS 9-5-2008, Baltimore, Maryland Plasmacytoma Monoclonal proliferation of
More informationOutline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD
Outline A Disease Overview June 3, 2013 Andrew Eisenberger, MD Assistant Professor of Medicine Hematology/Oncology Columbia Presbyterian Medical Center Introduction Epidemiology/Risk Factors Clinical Features/Diagnostic
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationPERIPHERAL STEM CELL TRANSPLANT INTRODUCTION
PERIPHERAL STEM CELL TRANSPLANT INTRODUCTION This booklet was designed to help you and the important people in your life understand the treatment of high dose chemotherapy with stem cell support: a procedure
More informationA rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml
IJCRI 2011;2(9):16-20. Rajendiran et al. 16 CASE REPORT OPEN ACCESS A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml Govarthanan Rajendiran, Linda Green,
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More information